Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Holding ANAB?
Track your performance easily
ANAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.36 - $41.31
Previous Close$30.49
Volume375.52K
Average Volume (3M)321.98K
Market Cap
$967.30M
Enterprise Value$633.44M
Total Cash (Recent Filing)$350.80M
Total Debt (Recent Filing)$16.95M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 07, 2024EPS Estimate
-$1.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.34
Shares Outstanding30,184,531
10 Day Avg. Volume344,251
30 Day Avg. Volume321,979
Standard Deviation0.21
R-Squared0.00512
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)93.33
Price to Sales (P/S)30.20
Price to Cash Flow (P/CF)-10.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.79
Enterprise Value/Gross Profit36.92
Enterprise Value/Ebitda-4.03
Forecast
1Y Price Target
$55.25Price Target Upside79.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsANAB's PD-1 agonist rosnilimab demonstrated compelling preclinical results by effectively targeting and depleting inflammatory T-cells by 90%, showing potential as a treatment for ulcerative colitis.
Financial PerformanceA $100M direct offering was announced, including participation from SAN FP, with shares priced at a 10% premium, indicating strong investor confidence in ANAB's future prospects.
Pipeline DevelopmentThe stock's ~$1B equity valuation and its pipeline of novel I&I drug candidates with blockbuster potential, including promising Ph2 and Ph1 drugs, highlight significant growth opportunities.
Bears Say
Competitive PressureThe next minor stock catalyst could be competitor LLY's PD-1 agonist (peresolimab) updates, which might impact ANAB if LLY advances their drug.
Financial Performance2Q net loss of $46.7M compared to the estimate of $41.6M and consensus of $22.1M.
Product DiscontinuationThe discontinuation of LY3361237 was due to the lack of efficacy, attributed to the drug's antagonistic properties and poor Fc engagement.
---
Ownership Overview
43.61% Insiders
19.20% Mutual Funds
1.63% Other Institutional Investors
24.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $13.36 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Nov 07, 2024 which is in 8 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Aug 05, 2024. The company reported -$1.71 earnings per share for the quarter, missing the consensus estimate of -$1.041 by -$0.669.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$1.7.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,199,814 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.71 in its last earnings report, missing expectations of -$1.041. Following the earnings report the stock price went down -0.896%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 6M.
---
AnaptysBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.25 (79.38% Upside)
$55.25 (79.38% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 572.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.48%
12-Months-Change
Fundamentals
Return on Equity
-214.89%
Trailing 12-Months
Asset Growth
-17.35%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Month Forecast
Average Price Target
$55.25
▲(79.38% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
-26.61%
reiterated a buy rating last month
Copying Anupam Rama's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -26.61% per trade.
---